AFT Pharmaceuticals announces agreement with Alexso

AFT Pharmaceuticals (ASX: $AFP) has announced an agreement with Alexso to distribute Combogesic® (Maxigesic Rapid Tablets) in the United States, the largest pharmaceutical market in the world. The company's Managing Director, Dr Hartley Atkinson, expressed delight in the partnership and the anticipation of launching their second patented pharmaceutical in the United States market during this financial year.

Executive Commentary on Partnership and Product Launch

Dr Hartley Atkinson, Managing Director of AFT Pharmaceuticals, expressed the company's delight in the partnership with Alexso, an established pharmaceutical distribution company prioritizing non-opioid pain management solutions. He also highlighted the anticipation of launching their second patented pharmaceutical in the United States market during this financial year. Troy Farahmand, President of Alexso, echoed the enthusiasm, stating that the partnership aligns perfectly with their commitment to offering physicians effective alternatives to opioids and will play a crucial role in their mission to combat pain while reducing the reliance on addictive opioid medications.

Summary of AFT Pharmaceuticals Announcement

AFT Pharmaceuticals (ASX: $AFP) has announced an agreement with Alexso to distribute Combogesic® (Maxigesic Rapid Tablets) in the United States, the largest pharmaceutical market in the world. The company's Managing Director expressed delight in the partnership and the anticipation of launching their second patented pharmaceutical in the United States market during this financial year. The partnership with Alexso aligns with their commitment to offering non-opioid pain management solutions. AFT's negotiations are also progressing with other distributors for additional specific market channels in the United States. This strategic move reflects AFT's ambition to expand its presence and offer effective alternatives to opioids in the global pharmaceutical market.